VW
Therapeutic Areas
Theriva Biologics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VCN-01 (zabilugene almadenorepvec) | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 |
| VCN-01 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 |
| Albumin Shield™-Enabled OV | Undisclosed Solid Tumors | Preclinical |
Leadership Team at Theriva Biologics
SS
Steven Shallcross
Chief Executive Officer, Chief Financial Officer, Director
MC
Manel Cascallo
General Director, EU Subsidiary
RA
Ramon Alemany
Scientific Advisor
GC
Gabriel Capellá
Scientific Advisor
JT
Josep Tabernero
Scientific Advisor
JJ
Jeffrey J. Kraws
Chairman of the Board
JW
Jeffrey Wolf
Director
JM
John Monahan
Director